Literature DB >> 1398761

Down-regulation of a spontaneous arthritis in male DBA/1 mice after administration of monoclonal anti-idiotypic antibodies to a cross-reactive idiotope on anti-collagen antibodies.

C Nordling1, S Kleinau, L Klareskog.   

Abstract

We recently described a spontaneously occurring, inflammatory and erosive joint disease in male DBA/1 mice. A major question is whether specific immune reactions are involved in eliciting this disease. The possibility that collagen autoimmunity might constitute one pathogenic factor was particularly interesting as this spontaneous arthritis appears to be genetically restricted in a way similar to collagen-induced arthritis. In the present study, we demonstrate increased serum antibody levels to collagen II in a fraction of the male DBA/1 mice, but not in age-matched female controls. Administration of antibodies with an anti-idiotypic activity to anti-collagen II antibodies and with an affinity for determinants present on isolated syngeneic IgG Fc but not on intact IgG, was shown to interfere with the development of the spontaneous arthritis in a manner similar to that earlier documented for collagen arthritis. These observations suggest that mechanisms similar to those operating in collagen-induced arthritis may also be found in the spontaneously occurring arthritis in male DBA/1 mice.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1398761      PMCID: PMC1421579     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  8 in total

1.  Down-regulation of collagen arthritis after in vivo treatment with a syngeneic monoclonal anti-idiotypic antibody to a cross-reactive idiotope on collagen II auto-antibodies.

Authors:  C Nordling; R Holmdahl; L Klareskog
Journal:  Immunology       Date:  1991-04       Impact factor: 7.397

2.  Characterization of the antibody response in mice with type II collagen-induced arthritis, using monoclonal anti-type II collagen antibodies.

Authors:  R Holmdahl; K Rubin; L Klareskog; E Larsson; H Wigzell
Journal:  Arthritis Rheum       Date:  1986-03

3.  Patterns of autoreactivity to collagen type II in autoimmune MRL/l mice.

Authors:  A Tarkowski; R Holmdahl; K Rubin; L Klareskog; L A Nilsson; K Gunnarsson
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

4.  Monoclonal antibodies with exclusive reactivity against parathyroid cells and tubule cells of the kidney.

Authors:  C Juhlin; R Holmdahl; H Johansson; J Rastad; G Akerström; L Klareskog
Journal:  Proc Natl Acad Sci U S A       Date:  1987-05       Impact factor: 11.205

5.  A monoclonal antiidiotypic antibody with rheumatoid factor activity defines a cross-reactive idiotope on murine anticollagen antibodies.

Authors:  C Nordling; R Holmdahl; L Klareskog
Journal:  J Immunol       Date:  1991-06-15       Impact factor: 5.422

6.  Incidence of arthritis and autoreactivity of anti-collagen antibodies after immunization of DBA/1 mice with heterologous and autologous collagen II.

Authors:  R Holmdahl; L Jansson; D Gullberg; K Rubin; P O Forsberg; L Klareskog
Journal:  Clin Exp Immunol       Date:  1985-12       Impact factor: 4.330

7.  Secretion of antibodies to types I and II collagen by synovial tissue cells in patients with rheumatoid arthritis.

Authors:  A Tarkowski; L Klareskog; H Carlsten; P Herberts; W J Koopman
Journal:  Arthritis Rheum       Date:  1989-09

8.  Generation of monoclonal rheumatoid factors after immunization with collagen II-anti-collagen II immune complexes. An anti-idiotypic antibody to anti-collagen II is also a rheumatoid factor.

Authors:  R Holmdahl; C Nordling; K Rubin; A Tarkowski; L Klareskog
Journal:  Scand J Immunol       Date:  1986-08       Impact factor: 3.487

  8 in total
  1 in total

1.  Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis.

Authors:  Rik J U Lories; Inge Derese; Frank P Luyten
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.